EU assessment of high-risk medical devices faces in-depth review

Topics: Medical devices, regulation, cardiology, orthopaedics
Embargo: 16 April 2021 at 05:00 CEST

Sophia Antipolis, 16 April 2021: The methods for evaluating high-risk medical devices are set to be reviewed in the EU-funded CORE-MD project, which holds its kick-off meeting today.

CORE-MD is the first formalised group of stakeholders in Europe working together to identify ways to enable the scientific, fair, and systematic evaluation of medical devices. Led by the European Society of Cardiology (ESC) in close partnership with the European Federation of National Associations of Orthopaedics and Traumatology (EFORT), the consortium includes 22 partners involved in the development, evaluation, approval and certification, clinical use, and monitoring of medical devices.

The project launch comes as new EU medical device regulations come into force on 26 May 2021, increasing the requirements for clinical evidence on high-risk medical devices. However, there are no specific EU recommendations on the design and conduct of trials for high-risk devices. In addition, medical device developers have expressed concerns that the new rules may inhibit innovation and delay market access.

More than 50% of high-risk implantable medical devices in Europe are used in cardiology and orthopaedics – such as heart valves and hip replacements – and CORE-MD will focus primarily on these areas. The three-year project begins with a systematic review of methodologies used in clinical trials to evaluate high-risk medical devices, including statistical methods and the utility of patient-reported outcomes for regulatory decisions.

CORE-MD will propose how to generate evidence using innovative methodologies like randomised registry trials and how to assess artificial intelligence algorithms that are designated as medical devices. The project will also examine how to evaluate medical devices used in children. Advice will be provided on ways to extract maximum value from real-world evidence including medical device registries and clinical practice.

Recommendations from the CORE–MD consortium will be submitted to the Working Group on Clinical Investigation and Evaluation of the European Commission, so that they can be considered as the basis for developing EU guidance documents or common specifications.

CORE-MD Scientific Coordinator Professor Alan Fraser of the ESC said: “High-risk medical devices should be approved based on scientific and clinical evidence. Experts need to advise how regulators can achieve an appropriate balance between innovation, safety, efficacy and cost-effectiveness. We look forward to doing that through our unique collaboration of medical associations, EU regulators, national public health institutes, notified bodies, academic institutions, patient groups, and health technology assessment agencies, with participation of manufacturers’ trade associations.”

Professor Rob Nelissen of EFORT said: “Ultimately, the overall impact of CORE-MD will be to improve the benefit/risk ratio of new implantable medical devices and other high-risk devices for patients. We aim to see wider adoption of optimal methodologies for clinical investigations by both researchers and manufacturers, fewer approvals with limited evidence, and greater transparency of standards.”

ENDS
Authors: ESC Press Office & EFORT

ESC Press Office
Tel: +33 (0)4 89 87 20 85
Mobile: +33 (0)7 8531 2036
Email: press@escardio.org
Follow us on Twitter @ESCCardioNews

Notes
EFORT
Email: media@efort.org
Follow us on Twitter @EFORTnet

Funding:

This project has received funding from the European Union’s Horizon 2020 Research and Innovation Programme under grant agreement No 965246

References
1CORE-MD: Coordinating Research and Evidence for Medical Devices.

About the European Society of Cardiology
The European Society of Cardiology brings together health care professionals from more than 150 countries, working to advance cardiovascular medicine and help people lead longer, healthier lives.

About the European Federation of National Associations of Orthopaedics and Traumatology (EFORT)
The European Federation of National Associations of Orthopaedics and Traumatology (EFORT) works together with its membership network and partners to restore and secure mobility, musculoskeletal health and quality of life.

The CORE-MD consortium includes four European medical professional associations, one European umbrella organisation for patient groups, eight academic institutions, one public body (Region Uppsala), three national regulatory authorities of EU member states, two national public health institutes, two health technology assessment bodies and one trade association for European notified bodies:
Academisch Ziekenhuis Leiden (Leiden University Medical Centre, the Netherlands)
Área de Evaluación de Tecnologías Sanitarias de Andalucía de la Fundación Pública Andaluza Progreso y Salud – AETSA-FPS (HTA Unit within the Progress and Health Foundation, Seville)
Biomedical Alliance in Europe
European Academy of Paediatrics
European Association of Notified Bodies for Medical Devices
European Federation of National Associations of Orthopaedics and Traumatology
European Patients Forum
European Society of Cardiology
Göteborgs Universitet (Gothenburg University)
Health Products Regulatory Authority (Dublin)
HTA Austria - Austrian Institute for Health Technology Assessment GmbH (Vienna)
Insel Gruppe Ag (University Hospital Bern)
Istituto Superiore di Sanita (Italian National Institute of Health, Rome)
Katholieke Universiteit Leuven
Laegemiddelstyrelsen (Danish Medicines Agency, Copenhagen)
Politecnico di Milano
Region Uppsala
Rijksinstituut Voor Volksgezondheid en Milieu (National Institute for Public Health and the Environment, Bilthoven, The Netherlands)
Royal College of Surgeons in Ireland
The Chancellor, Masters and Scholars of the University of Oxford
UMIT- Private Universität für Gesundheitswissenschaften, Medizinischeinformatik und Technik GmbH (University for Health Sciences, Medical Informatics and Technology, Hall in Tirol, Austria)
Urzad Rejestracji Produkow Leczniczych, Wyrobow Medycznych I Produktow Biobojczych (Office for Registration of Medicinal Products, Medical Devices and Biocidal Products, Warsaw)

For further information
https://cordis.europa.eu/project/id/965246
www.core-md.eu